ESMO 2022 | STAMPEDE: Post-hoc analysis of nodal metastases

Name: STAMPEDE: Post-hoc analysis of nodal metastases
Uploaded: 2022-09-11T00:00:00Z
Duration: 1 min 45 s

Aine Haran • 11 Sep 2022

ESMO 2022

Genitourinary Cancer Prostate Cancer Abiraterone Docetaxel

STAMPEDE

Aine Haran, BMBS, MRCS, The Christie and Salford Royal Hospitals, Manchester, UK, discusses a post-hoc analysis of nodal metastases in the STAMPEDE trial (NCT00268476) which investigated systemic therapies for advanced prostate cancer. The analysis included a study of nodal burden in the docetaxel and abiraterone arms of the trial and also assessed the use of nodal burden as a predictive or prognostic biomarker. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.